The ASCO Annual Meeting is hosted by the American Society of Clinical Oncology. The meeting offers presentations on the latest research in oncology care.
The Efficacy, Safety of Lutetium Lu 177 Dotatate for Advanced Midgut Neuroendocrine Tumors
June 4th 2021Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, discusses the efficacy and safety of lutetium Lu 177 dotatate for midgut neuroendocrine tumors.
An Overview of the Phase 3 Trial Assessing Lutetium Lu 177 Dotatate for Midgut Neuroendocrine Tumors
June 4th 2021Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, gives an overview of the phase 3 trial assessing lutetium Lu 177 dotatate for midgut neuroendocrine tumors.
Researchers Recommend Interventions as New Standard of Care for Patients with Oral Anticancer Agents
June 3rd 2020A study found that nurse-led follow-up and mobile health app leads to improved relative dose intensity, patient experiences, hospitalizations and their duration, and the rate of treatment-related grade 3 or higher toxicities.